main content start
How do you like the content?
Myelodysplastic Syndromes 10m 25s

Recommendations to improve Real World outcomes in MDS patients

Downloadable slides curated by experts

Please watch the video to access Medslides

Published 11 Jul 2022
Cytogenetic heterogeneity like deletion in chromosome 5, 7 and Trisomy 8 are increasingly observed in patients with Myelodysplastic Syndromes. Genetic mutations like ASXL1 & TET2 are increasingly found in patients with MDS.
azactidine cyotgenetic heterogenity mds

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Perks of registering with us
Access to Online/Offline Events
Personalized Content
Access to all Features
Hi, can I help?
Chat SupportX
Support Team
Hello, how can I help you today?
Please select one of the below options.

Find Information

Unable to Login or Register

Want to share feedback